| Date | Title | Description |
| 07.01.2026 | Andera Partners Leads $67 Million Series A Financing in Spiro Medical to Develop a Neuromodulation System for Asthma. | The financing included a syndicate of venture investors led by Andera Partners (Paris), Omega Funds (Geneva) and Sherpa Healthcare Partners (Cayman Islands) and joined by HSG (Hong Kong), Supernova Invest (Paris), Northern Light Venture Cap... |
| 26.07.2024 | Andera Partners Co-Leads $196 Million Round for Kestra Medical and Welcomes Raymond W. Cohen to Board of Directors | Kestra Medical is an American company also present in Ireland, which has developed and commercializes a medical device: a vest equipped with a portable defibrillator for patients at risk of sudden cardiac arrest.
The $196 million financing ... |
| 11.05.2020 | Axonics Modulation Technologies raises $130 million via public offering | Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Syst... |
| 05.08.2019 | Axonics® Announces Second Quarter 2019 Financial Results and Operational Update | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, repor... |
| 05.03.2019 | Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfuncti... |
| 31.10.2018 | Axonics raises $120 million via an Initial Public Offering on NASDAQ | Utrecht (The Netherlands), Cambridge (United States) - Axonics Modulation Technologies announced its Initial Public Offering and listing on the NASDAQ exchange. Shares in the IPO are issued to institutional investors in the US and Europe, r... |
| 04.04.2018 | Axonics executes $40M financing to commercialize neuromodulation device | Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial that will set it up to market the device... |
| 04.04.2018 | Axonics executes $40M financing to commercialize neuromodulation device | Axonics has secured $40 million to support commercialization of its neuromodulatory treatment of urinary and bowel dysfunction. The financing comes as Axonics closes in on the end of a clinical trial that will set it up to market the device... |
| 03.04.2018 | Axonics Announces $40 Million Financing | Axonics Modulation Technologies, Inc., a privately-held developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $40.1 million fin... |
| 03.04.2018 |
Axonics Finds $40M In Funding
| Irvine-based Axonics Modulation Technologies, which is developing medical devices for treating urinary and bowel dysfunction, said today that it has raised $40.1M in financing, split between $20.1M in equity and $20M in a credit facility. T... |
| 07.07.2017 | Term Sheet — Friday, July 7 | BIG TOP, BIG FOOD, SLOW DEATH
THE LP FACTOR: The past week’s news reports on sexual harassment in the venture capital industry have created hope that much-needed cultural change is coming to Silicon Valley. But many of my conversations with... |
| 07.07.2017 | Axonics snags another $20M+ in oversubscribed series C | Axonics Modulation Technologies raised $20.5 million in the second closing of its series C financing, which will give the company a boost as it prepares for FDA submission.
Along with the $14.5 million Axonics bagged in May, the series C fu... |
| 07.07.2017 | Axonics snags another $20M+ in oversubscribed series C | Axonics Modulation Technologies raised $20.5 million in the second closing of its series C financing, which will give the company a boost as it prepares for FDA submission.
Sponsored by Agilent Technologies
How would you like to win free be... |
| 06.07.2017 | Axonics Announces $20.5 Million Second Closing of its Series C Financing | Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $20.5 million second closing of it... |
| 06.07.2017 |
Axonics Ups Series C Funding By $20.5M
| Irvine-based medical device maker Axonics Modulation Technologies has raised $20.5M more in its Series C funding, bringing the funding in the round to a total of $35M. According to Axonics, the second closing included Gilde Healthcare, and ... |
| 06.07.2017 | Axonics Holds $20.5M Second Closing of Series C Financing | Axonics Modulation Technologies, Inc., an Irvine, Calif.-based developer of a rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, completed a $20.5m second closing of its Series C financin... |
| 06.07.2017 | Axonics Pulls In $20.5M Series C Funding |
IRVINE, CA, Axonics Modulation Technologies, a developer of the first rechargeable sacral neuromodulation system for the treatment of urinary and fecal dysfunction, has closed $20.5 million in financing.
>> Click here for more fund... |
| 04.05.2017 | Term Sheet — Thursday, May 4 | ET CETERA
New money: Heap, an analytics software company, has raised $27 million in Series B funding led by NEA and Menlo Ventures with participation from Initialized Capital and Pear VC. Heap CEO and co-founder Matin Movassate created the ... |
| 04.05.2017 | Axonics Modulation Technologies Grabs $14.5M |
IRVINE, CA, Axonics Modulation Technologies, an implantable neuromodulator device manufacturer, raised $14.5 million in Series C funding.
>> Click here for more funding data on Axonics Modulation Technologies
>> To export Ax... |
| 03.05.2017 | Axonics Raises $14.5M Series C from Cormorant Asset Management | IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $... |
| 03.05.2017 | Axonics Raises $14.5M Series C from Cormorant Asset Management | IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $... |
| 02.05.2017 |
Axonics Raises $14.5M
| Irvine-based Axonics, a developer of medical devices to treat urinary and fecal dysfunction, has raised $14.5M in a Series C funding round, the company announced this morning. The company said the funding is the first close of a targeted $3... |
| 02.05.2017 | Axonics Announces $14.5 Million First Close of Series C Financing | Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $14.5 million first closing of its... |
| 02.05.2017 | Axonics Raises $14.5M in First Close of Series C Financing | Axonics Modulation Technologies, Inc., an Irvine, Calif.-based developer of a rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, completed a $14.5m first closing of its $30m planned Serie... |
| 18.04.2017 | Axonics to Present Results of the RELAX-OAB Clinical Study at the International Neuromodulation Society World Congress | Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that initial results from its prospective, multicenter cli... |
| 23.02.2017 | Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology | Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has gra... |
| 22.12.2015 | Daily funding roundup - December 22, 2015 | Axonics completed $38.5M; Shuttl raised $20M; NextInput Inc., received $8M funding
Motorola Solutions has made a strategic investment in BlueLine Grid, an emerging technology company that previously received an investment from In-Q-Tel, the... |
| 21.12.2015 | Axonics Modulation Technologies Nets $38.5M |
IRVINE, CA, Developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million Series B financing.
>> Click here for more funding data on Axonics Modulation Technologies
... |
| 21.12.2015 | Axonics Modulation Technologies Announces $38.5 Million Series B Financing | Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million Series B financing.
Proceeds from the financing will be used to conduct a... |
| 21.12.2015 |
Axonics Modulation Technologies Raises $38.5M
| Irvine-based Axonics Modulation Technologies, which develops medical devices for treating overactive bladder and other issues, has raised $38.5M in a Series B funding. The funding came from Advent Life Sciences, Cormorant Asset Management, ... |
| 21.12.2015 | Axonics Modulation Technologies raises $38.5M for device clinical study in overactive bladder patients | Sacral Neuromodulation is the only approved solution that can treat both urinary and fecal incontinence with a single implant provided via a short surgical procedure, which functions with the help of external controls and chargers. The ther... |
| 21.12.2015 | Axonics Modulation Technologies Completes $38.5M Series B Financing | Axonics Modulation Technologies, Inc., an Irvine, CA-based developer of miniaturized implantable Sacral Neuromodulation technology, completed a $38.5m Series B financing.
Backers included new investors Advent Life Sciences and Cormorant Ass... |
| 30.04.2015 | Neuromodulation startup raises $17.3M for implantable device that treats incontinence | The company licensed its technology from the Alfred Mann Foundation and launched in 2013. The team’s made up of execs coming from Vessix Vascular, before it was sold to Boston Scientific in 2012.
Medtronic seems to have cornered the market ... |
| 31.03.2014 | Axonics Modulation Technologies Completes $32.6M Series A Financing | Axonics Modulation Technologies, Inc., a Irvine, Calif.-based developer of novel implantable neuromodulation technology, completed a $32.6m Series A financing.
The round was led by Edmond de Rothschild Investment Partners (EdRIP), with part... |
| 28.03.2014 | Axonics raises $33M for its neuromodulation tech | Axonics Modulation Technologies said it drummed up a $32.6 million Series A round for the neuromodulation technology it’s developing to treat chronic pain and overactive bladder.
Irvine, Calif.-based Axonics said the round was led by Edmond... |
| 25.03.2014 | Axonics Modulation Technologies Inks $32.6M in Series A |
IRVINE, CA, Developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million in Series A.
>> Click here for more funding data on Axonics Modulation Technologies
>> To export Ax... |
| 25.03.2014 | Axonics Modulation Technologies Announces $32.6 Million Series A Financing Led by Edmond De Rothschild Investment Partners | Axonics Modulation Technologies, Inc., a developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million Series A preferred stock financing.
Axonics holds an exclusive license for its miniat... |
| 25.03.2014 |
Axonics Modulation Technologies Gets $32.6M For Medical Device
| Irvine-based Axonics Modulation Technologies has raised $32.6M in a Series A funding, the company announced this morning. Axonics--which is developing implantable neuromodulation technology used for treating chronic pain and overactive blad... |
| - | Neuromodulation startup raises $17.3M for implantable device that treats incontinence | SoCal startup Axonics Modulation Technologies has raised $17.3 million, according to a new regulatory filing. Based in Irvine, the startup is developing implantable sacral neuromodulation devices that treat conditions like overactive bladde... |
| - | Axonics Modulation Technologies raises $38.5M for device clinical study in overactive bladder patients | Axonics Modulation Technologies has developed a small implantable device that uses Sacral Neuromodulation technology designed to treat those suffering from overactive bladder, fecal incontinence and urinary retention.
The company announced ... |
